ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,701.70
0.96%
S&P ASX All Technology
3,075.00
0.84%
Brent Oil
81.295
0.00%
US Dollar vs AUD
1.49858
-0.15%
Bitcoin
67,605.85
0.18%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Denali Therapeutics Inc (DNLI)

  7. Denali Therapeutics Inc (DNLI) News

DNLI

Denali Therapeutics (DNLI)

Denali Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:DNLI
DateTimeSourceHeadlineSymbolCompany
01/06/202406:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
08/05/202406:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
08/05/202406:01GlobeNewswire Inc.Denali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
01/05/202422:00GlobeNewswire Inc.Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform TrialNASDAQ:DNLIDenali Therapeutics Inc
02/03/202408:51Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:DNLIDenali Therapeutics Inc
28/02/202400:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
28/02/202400:05GlobeNewswire Inc.Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
28/02/202400:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
28/02/202400:00GlobeNewswire Inc.Denali Therapeutics Announces $500 million Private Placement Equity FinancingNASDAQ:DNLIDenali Therapeutics Inc
17/02/202400:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
16/02/202413:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
16/02/202413:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
16/02/202413:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
15/02/202408:59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
15/02/202408:43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
14/02/202412:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
14/02/202412:18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
14/02/202412:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
13/02/202408:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
08/02/202400:00GlobeNewswire Inc.Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™NASDAQ:DNLIDenali Therapeutics Inc
02/02/202400:00GlobeNewswire Inc.Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™NASDAQ:DNLIDenali Therapeutics Inc
13/01/202412:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
12/01/202409:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
11/01/202408:09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
10/01/202411:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
10/01/202411:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
10/01/202411:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
10/01/202411:20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
09/01/202400:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
09/01/202400:00GlobeNewswire Inc.Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage DiseasesNASDAQ:DNLIDenali Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:DNLI

Your Recent History

EU
BEB157685178
Belfius 1.9% 01sep2024 Cv
BIT
P117U5
Bnp Paribas Issuance
BIT
UV8BSB
UniCredit Bank
TSX
AH.DB.B
Aleafia Health
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved